FIELD: medicine; pharmacology.
SUBSTANCE: invention refers to application of miliacin as agent limiting lymphotoxin effect of methotrexate.
EFFECT: extended range of agents limiting lymphotoxin effect of methotrexate.
3 tbl, 8 dwg, 1 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF PROTECTING POST-VACCINATION IMMUNITY TO TETANUS ANATOXIN AGAINST METHOTREXATE-INDUCED DEPRESSION | 2008 |
|
RU2394577C1 |
ANTIMUTAGENIC AGENT | 2019 |
|
RU2698204C1 |
AGENT FOR REDUCING SYSTEMIC PATHOLOGIC ENDOTOXINEMIA | 2014 |
|
RU2564918C1 |
THYMUS DEFICIENCY SIMULATING METHOD | 0 |
|
SU1040510A1 |
PEPTIDE HAVING EFFECT ON REGENERATION OF HOMOGENIC AND IMMUNE SYSTEMS, AND PHARMACEUTICAL COMPOSITION BASED THEREON | 1996 |
|
RU2121480C1 |
AGENT ENHANCING IMMUNOGENIC PROPERTY OF TETANUS ANATOXIN | 2003 |
|
RU2244548C1 |
MEDICATION INCREASING ANTITUMOUR EFFECT OF METHOTREXATE | 2009 |
|
RU2411947C1 |
AGENT SHOWING IMMUNOSTIMULATING EFFECT | 1995 |
|
RU2093162C1 |
AGENT FOR PROTECTION, RETENTION AND RECOVERY OF LYMPHOID ORGANS IN VIBRATION EFFECT | 2002 |
|
RU2233660C2 |
PEPTIDE POSSESSING IMMUNOGEROPROTECTIVE EFFECT, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHOD FOR ITS USING | 2006 |
|
RU2301074C1 |
Authors
Dates
2008-11-10—Published
2007-03-19—Filed